EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology

KyoungSoo Lim, Xu Sue Zhu, Diansong Zhou iD, Song Ren, Alex Phipps iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3308 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von KyoungSoo Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, United States Food and Drug Administration, Drug Approval, Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies, by enabling the targeting of more than one disease‐associated antigen or engaging immune effector cells, have both advantages and challenges compared with a combination of two different biological products. As of December 2023, there are 11 U.S. Food and Drug Administration–approved BsAb products on the market. Among these, 9 have been approved for oncology indications, and 8 of these are CD3 T‐cell engagers. Clinical pharmacology strategies, including dose‐related strategies, are critical for bispecific antibody development. This analysis reviewed clinical studies of all approved bispecific antibodies in oncology and identified dose‐related perspectives to support clinical dose optimization and regulatory approvals, particularly in the context of the Food and Drug Administration's Project Optimus: (1) starting doses and dose ranges in first‐in‐human studies; (2) dose strategies including step‐up doses or full doses for recommended phase 2 doses or dose level(s) used for registrational intent; (3) restarting therapy after dose delay; (4) considerations for the introduction of subcutaneous doses; (5) body weight vs. flat dosing strategy; and (6) management of immunogenicity. The learnings arising from this review are intended to inform successful strategies for future bispecific antibody development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificUnited States Food and Drug AdministrationDrug ApprovalNeoplasmsHumansUnited StatesDose-Response Relationship, DrugDrug DevelopmentAntineoplastic Agents, ImmunologicalPharmacology, ClinicalAnimals

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts, USA.
  • Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Diansong Zhou, Alex Phipps

Zitieren

APA

Lim, K., Zhu, X. S., Zhou, D., Ren, S., & Phipps, A. (2024). Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3308

Vancouver

Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3308

BibTeX
@article{Lim2024,
  author = {Lim, KyoungSoo and Zhu, Xu Sue and Zhou, Diansong and Ren, Song and Phipps, Alex},
  title = {Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3308}
}
Kostenlos starten →